News Sobi plans filings for gout drug after phase 3 readout SEL-212 will compete with Horizon's fast-growing Krystexxa if approved by the FDA.
News AZ considers options as US gout drug deal backfires Ironwood tears up licensing agreement after sales disappoint
News FDA approves Ironwood's gout combination drug Good news for Ironwood, which forecast annual sales of up to $300m, despite black box kidney failure warning.
News AZ sells US, EU and Latin America rights to gout drug AZ focused on sales target set by CEO Pascal Soriot.
R&D Reuters Pharma USA 2024 – Meruno Perugini Innovation in pharma comes in many forms, but at the end of the day what the industry cares about is results.
Digital Fixing clinical trial data management It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.